WHAT WE DO

Biohope is an early commercial stage R&D company dedicated to the development of precision medicine IVD tools and unique patient knowledge for chronic inflammatory conditions. Founded in 2015, it has received 3.8M EUR funding through the European Commission’s H2020 program, and more than 2M EUR through private funding . It employs 19 professionals in R&D, IT, Medical Affairs, Financial, Legal, Regulatory, Quality Control and BD&L.

Biohope lead product, Immunobiogram®, is a novel and unique, patented in vitro diagnostic device which generates a report for the physicians to optimize each individual immunosuppressive therapy. It is a combination of a bioassay and database analysis tools .

The Immunobiogram® in Kidney Transplantation is the first product from our technological platform. We have successfully finished a National and an International clinical study (performed in Spain, USA, Germany, Denmark, Poland) that have  demonstrated the effectiveness of Immunobiogram®

We have a patent published for EU, a PCT ongoing, an ISO 13485 certification, and a CE mark expected by Q3 2020.

In our pipeline, based on Immunobiogram® technology, adaptation is ongoing for Rheumatoid Arthritis , and planned for Nefritis Lupica, and for other conditions that require a patient to be on immunosupressants.

“Biohope has delivered exceptional results with significant immediate or potential impact. The Beneficiary is a perfect example of a SME Instrument successful company, where hard work combined with brilliant ideas, courage and EU financing result in very promising and interesting primary results.”

(2018 European Commission Report)

ENDORSEMENTS AND AWARDS

Thanks to the effort and commitment of our excellent Team, several organizations and institutions have recognized our achievements. Likewise, media are increasingly picking up news about Biohope.

ORGANIZATIONS

The National Transplant Organization of Spain, the most renowed transplant organization in Europe, supported this project to be scaled up to European scope.

ORGANIZATIONS

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement Nº 733248.